Tekla Life Sciences Investors (HQL) Cash Flow Statement

The stark divergence between accounting profits and cash reality suggests that HQL's reported net income is heavily reliant on unrealized valuation adjustments rather than cash-generative investment activity. Investors should monitor this gap, as it implies that the fund's ability to fund distributions is not supported by its underlying operational cash flow.

The persistent negative FCF margins, such as the -11.0% observed in 2025Q4, suggest that the fund is likely liquidating assets or utilizing capital reserves to meet its managed distribution obligations. This trend warrants further investigation into whether the current payout structure is sustainable without eroding the long-term capital base.

The reliance on capital distributions in the absence of positive operating cash flow suggests a potential for destructive return of capital, which may impair the fund's future investment capacity. Analysts should scrutinize whether these distributions are being funded by the liquidation of core holdings rather than recurring investment income.